00:00There are about 330,000 people affected by vitiligo in Italy, a little-known condition,
00:10yet it is a chronic autoimmune pathology that affects between 0.5 and 2% of the world population.
00:18It is very visible due to the characteristic white spots on the skin
00:22and therefore has a strong impact from a social, psychological and emotional point of view.
00:26It is also estimated that the cost of treatment is about 500 million euros per year.
00:31Biofarmaceutica Insight has announced the free way by the Italian Pharmaceutical Agency
00:37to the reimbursement of ruxolitinib cream, a specific treatment for non-segmental vitiligo
00:44with facial interest in adults and teenagers starting from the age of 12.
00:49A decision that comes after the authorization and commercial admission
00:53by the European Medicinal Agency, communicated in 2023.
00:58Before a drug is distributed on the market, it must go through a long series of clinical studies
01:07and the latest, those of phase 3, have shown the effectiveness of this treatment
01:14which consists in the disappearance of more than 75% of vitiligo spots in at least 50% of patients.
01:25This, of course, in the long term. It is important to clarify this.
01:31It is not a therapy that we can do for a few weeks or a few months,
01:34but we have to keep it for a long time.
01:37Because the longer we keep the therapy, the more we will get the benefit.
01:42It will be possible to access the treatment exclusively on prescription of hospital centers
01:47or dermatologists.
01:49Ruxolitinib is the first and only treatment for vitiligo and is the result of the Insight research.
01:55The drug has been developed by our researchers and has an intrinsic value of innovation,
02:00not only for its mechanism of action, but above all for the formulation.
02:06Because it is the first Jack inhibitor developed in topical formulation,
02:10therefore with a treatment mode that goes precisely in the direction of treating and targeting
02:15the cutae, which is the target organ of vitiligo.
Comments